|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
Acquired_by_Purdue_Pharma_Inc.
|
|
gptkbp:advertising
|
controversial campaigns
|
|
gptkbp:affiliation
|
gptkb:American_Pain_Society
|
|
gptkbp:businessModel
|
pharmaceutical sales
|
|
gptkbp:caseOutcome
|
bankruptcy settlement
|
|
gptkbp:CEO
|
gptkb:Craig_Landau
|
|
gptkbp:claims
|
opioid crisis
|
|
gptkbp:clinicalTrials
|
conducted for pain medications
|
|
gptkbp:communityEngagement
|
opioid education programs
|
|
gptkbp:communityImpact
|
opioid addiction awareness.
|
|
gptkbp:controversy
|
marketing practices
|
|
gptkbp:corporateSocialResponsibility
|
limited initiatives
|
|
gptkbp:employees
|
approximately 1,000
|
|
gptkbp:financialPerformance
|
declined post-lawsuits
|
|
gptkbp:financials
|
various health initiatives
|
|
gptkbp:founded
|
1996
|
|
gptkbp:founder
|
gptkb:John_Purdue_Gray
|
|
gptkbp:futurePlans
|
restructuring post-bankruptcy
|
|
gptkbp:headquarters
|
gptkb:United_States
gptkb:Stamford,_Connecticut
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Purdue Pharma L.P.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:internationalCooperation
|
limited_presence_outside_US
|
|
gptkbp:investmentFocus
|
research and development
private ownership
|
|
gptkbp:keyPeople
|
gptkb:Richard_Sackler
|
|
gptkbp:legalStatus
|
settlements
high-profile cases
|
|
gptkbp:market
|
global
private company
OxyContin (1996)
leading in opioids
|
|
gptkbp:marketingStrategy
|
focus on pain management
|
|
gptkbp:marketShare
|
significant in opioid market
|
|
gptkbp:notableEvent
|
gptkb:OxyContin
|
|
gptkbp:parentCompany
|
gptkb:Purdue_Pharma_Inc.
|
|
gptkbp:partnerships
|
various healthcare organizations
healthcare_providers
|
|
gptkbp:philanthropy
|
gptkb:Purdue_Pharma_Foundation
|
|
gptkbp:productLine
|
none reported
|
|
gptkbp:products
|
ongoing research
pharmacies and hospitals
opioid analgesics
|
|
gptkbp:publicPerception
|
negative due to opioid crisis
|
|
gptkbp:reform
|
OxyContin_(2010)
|
|
gptkbp:regulatoryCompliance
|
FDA_compliance
|
|
gptkbp:reputation
|
controversial due to opioid crisis
|
|
gptkbp:researchFocus
|
pain management
|
|
gptkbp:revenue
|
$3 billion (2018)
|
|
gptkbp:scholarships
|
2019
|
|
gptkbp:strategicGoals
|
pain management solutions
|
|
gptkbp:subsidiary
|
gptkb:Purdue_Pharma_Inc.
|
|
gptkbp:sustainabilityInitiatives
|
limited information
|
|
gptkbp:training
|
compliance and ethics
|
|
gptkbp:website
|
www.purduepharma.com
|